Dermatology News

Dermatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gelfand JM et al. – Current data are neither sufficient to completely rule out an increased risk of lymphoma associated with biologics, nor to firmly establish a causal relationship between biologics and lymphoma. Short– to intermediate–term treatment with biologics (e.g., up to 4 years) appears to be very safe with respect to lymphoma risk, especially with TNF–alpha inhibitors in which their potential risks appear to be well defined.

Today in Dermatologic Oncology...keeping you current

Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma
Medical Oncology, 12/04/09

Cutaneous lymphangioma circumscriptum: frog spawn on the skin
International Journal of Dermatology, 12/03/09

Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Cancer Epidemiology, 12/03/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address